Four-Year Feasibility and Safety Results of a Phase 1/2 Single-Arm Prospective Clinical Trial of Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy for Metachronous Oligometastatic Abdominopelvic Lymph Node and Soft Tissue Metastases
Abstract
Purpose: Metachronous oligometastases may represent a favorable disease state for local therapy after prior curative treatment. Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy (SMART) provides precise targeting of nodal and soft tissue metastases. The primary objective was to assess the feasibility and safety of SMART for abdominopelvic metachronous oligometastases. Secondary objectives included assessing rates of toxicities and evaluating local control (LC).
Methods and materials: Ten patients were enrolled with solid tumor metachronous abdominopelvic nodal or soft tissue metastases, ≤7 cm in maximal diameter, and ≤3 sites of active disease. All patients received 40 Gy in 5 fractions. Acute toxicities were graded per Common Terminology Criteria for Adverse Events v5 per-protocol follow-up over 1 year. Late toxicities and clinical outcomes were elucidated by chart review. LC, distant progression-free survival, and overall survival were analyzed using the Kaplan-Meier Method.
Results: Eight patients with prostate cancer and 2 with renal cell carcinoma were enrolled in the study. All patients were successfully treated with SMART per-protocol without complications. The median follow-up after SMART was 4.22 years. Three patients experienced acute grade 1 toxicities; there were no higher grade or late toxicities. Among these 10 patients, 4-year LC and overall survival were both 90%, and 4-year distant progression-free survival was 20%. Two patients (1 prostate…
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 10 participants or records.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.